Sumitomo Mitsui Ds Asset Management Company, LTD Alkermes Plc. Transaction History

Sumitomo Mitsui Ds Asset Management Company, LTD

$9.6 Billion
Q4 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$21.47 - $37.33 $199,134 - $346,235	-9,275 Closed	0 $0
Q1 2018 Apr 25, 2018	SELL	$53.61 - $67.26 $6,969 - $8,743	-130 Reduced 1.38%	9,275 $537,000
Q4 2017 Jan 25, 2018	SELL	$47.69 - $55.39 $88,560 - $102,859	-1,857 Reduced 16.49%	9,405 $514,000
Q3 2017 Oct 27, 2017	BUY	$49.16 - $54.45 $553,639 - $613,215	11,262	11,262 $572,000

Others Institutions Holding ALKS

# of Institutions

364

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$919 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$599 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$410 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$400 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$290 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.19B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Ds Asset Management Company, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Sumitomo Mitsui Ds Asset Management Company, LTD with notifications on news.

Account